8 things you need to know about eCTDs in China

Although eCTDs are a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.

Download PDF

Biotech Resources

8 things you need to know about eCTDs in China

EU Orphan Drug Designation – overcoming regulatory challenges

Preparing for the New Era of Hybrid Regulatory Inspections

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

How to better prepare patients for a cell or gene therapy trial

Communicating Value to Providers and Payers

Early planning can help you make the most of expedited regulatory pathways

Getting to ‘No’ fast is more important when you are small

How biotechs can strengthen their value story with advanced analytics

Want to run a patient-centric rare disease trial? Be site-centric

To create more rare disease drugs learn from the past

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

New endpoints for early-stage cancer are gaining regulatory traction

Five lessons for building an external control arm that regulators can use

Episode 17: Funding Biotech Innovation: How to Attract Investors

How emerging biotechs can enter the Chinese market and prosper

Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Biotech Showcase: Fireside Chat with Jamie Macdonald

Three strategies for articulating a coherent product value story

Master Protocol Trials: What Are the Elements of Success?